Jul. 14, 2026
SEATTLE, WASHINGTON — Sound Pharmaceuticals announced that it has completed enrollment in its second Phase 3 open-label study of SPI-1005 for the treatment of Ménière’s disease (MD). SPI-1005, an investigational oral anti-inflammatory drug, received FDA Breakthrough Therapy Designation in late 2025. Ménière’s disease is a complex inner ear disorder involving low- to mid-frequency hearing loss, tinnitus, vertigo, and dizziness. According

















